Lebovits Chaim's Form 4 filing
Brainstorm Cell Therapeutics Inc. (BCLI) · filed Apr 19, 2024
- Accession no.
- 0001104659-24-049027
- Filed
- Apr 19, 2024
- Trade date
- Apr 17-18, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. It was filed 2 days after the trade.
This filing was later replaced by the amendment 0001104659-24-084334 (Jul 31, 2024). Trade tables on this site use the amended version.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lebovits ChaimCIK 0001406302 | Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.